Jose A. Ferreira, MD
508 South Habana Avenue
Suite 340, Suite 240 & Suite 140
Tampa, FL 33609
Ph (813) 873-7367
Fax (813) 875-9722
jferreira@pensresearch.org
www.pensoftampabay.com

LICENSURE

1994 Florida State (active)
1991 New York State (not active)

CERTIFICATIONS

08/2014 – American Board of Psychiatry & Neurology Certification in Epilepsy
12/1997 - American Board of Clinical Neurophysiology (current)
11/1994 - American Board of Psychiatry & Neurology with Special Qualifications in Child Neurology
Initial Certification 11/30/1994
Pediatric Neurology Recertification 08/19/2004
Pediatric Neurology Recertification 02/03/2014
06/1988 – Federal Licensure Examination (FLEX)
09/1987 – Educational Commission for Foreign Medical Graduates (ECFMG)
07/1986 – Part II: FMGEMS
01/1986 – Part I: Foreign Medical Graduates Examination in Medical Sciences (FMGEMS)

EDUCATION

Universidad Central del Este (UCE), Dominican Republic
Degree: Doctor of Medicine 09/1982 – 12/1986

State University of New York (SUNY), Old Westbury, New York
Degree: Bachelor of Science in Biology 09/1977 – 07/1982

Amityville Memorial High School, New York
Degree: High School Diploma 09/1975 – 06/1977

OTHER ACTIVITIES

Medical School Class Vice-President (UCE)
Science Club Chairperson (SUNY)

GRADUATE TRAINING

Electroencephalography / Epilepsy Fellow
University of Miami School of Medicine
Program Director: R. E. Ramsay, MD 07/1993 – 06/1994

Pediatric Neurology Fellow
Schneider Children's Hospital, Long Island, NY
The Long Island Campus for Albert Einstein University School of Medicine
Program Director: Lydia Eviatar, MD 07/1990 – 06/1993

Adult Neurology Fellow
Long Island Campus for Albert Einstein University School of Medicine
Program Director: Ronald Kanner, MD 07/1990 – 06/1991

Pediatric Resident
University of Connecticut School of Medicine Affiliated Hospitals and Yale University School of Medicine Affiliated Hospitals
Program Director: Lyman Page, MD 07/1988 – 06/1990

MEMBERSHIPS

American Academy of Neurology (AAN)
American Epilepsy Society (AES)
American Clinical Neurophysiology Society (ACNS)
Child Neurology Society (CNS)
Fellow of the American Clinical Neurophysiology Society
Member of TGH/USF Comprehensive Epilepsy Center

LANGUAGES

Fluent in English and Spanish

PROFESSIONAL EXPERIENCE

Medical Advisor for Autism Program in the Dominican Republic 2010 – Present
Pediatric Neurology Division Chief: St Joseph's Children's Hospital
Tampa, FL 06/2004 – Present
Medical Director: Pediatric Epilepsy & Neurology Specialists, PA
Tampa, FL 04/2001 – Present
Attending Physician: Comprehensive Epilepsy Program,
University of South Florida (USF)/Tampa General Hospital, Tampa, FL 2000 – Present
Pediatric Neurologist: Child Neurology Specialists, CNS 05/1998 – 03/2001
Director: Seizure Monitoring Unit, All Children's Hospital
St Petersburg, FL 04/1997 – 05/1998
Director: Neurophysiology Laboratory, All Children's Hospital
St Petersburg, FL 04/1997 – 05/1998
Medical Director: Suncoast Comprehensive Pediatric Epilepsy Team
Florida 09/1995 – 05/1998
Pediatric Neurologist: Pediatric Neurology Associates, PA 07/1994 – 05/1998
Family Practice Preceptorship: Dr N. Scheiner, Seaford, NY 06/1987 – 05/1988

COMMITTEE APPOINTMENTS

Epilepsy Services Foundation Project Access Regional Collaborative
Committee Member, Tampa, FL 2011 – Present
Quality Assurance Committee, St. Joseph's Children's Hospital,
Tampa, FL 01/2003 – 2012
EMR Development Committee, St. Joseph's Children's Hospital,
Tampa, FL 10/2006 – 2012
Medical Executive Committee, St. Joseph's Children's Hospital,
Tampa, FL 01/2006 – 01/2009
Pharmacy and Therapeutics Committee, All Children's Hospital,
St. Petersburg, FL 01/1997 – 01/1998

ACADEMIC APPOINTMENTS

Clinical Assistant Professor
University of South Florida School of Medicine, Department of Pediatrics
Program Director: Lynn Ringenberg, MD 04/1999 – 2006

Clinical Associate Professor of Pediatrics University of South Florida School of Medicine Program Director: Lynn Ringenberg, MD	2006 – 2013
Adjunct Associate Professor of Pediatrics & Neurology University of South Florida School of Medicine	2013 – 2016
Clinical Associate Professor University of South Florida School of Medicine	2016 – 2022
Clinical Professor, Department of Pediatrics & Neurology USF Health Morsani College of Medicine	2022-Present

PROFESSIONAL APPOINTMENTS

Children's Medical Services Consultant	1994 – Present
Board Examiner for American Clinical Neurophysiology Society (ACNS)	2007
Board Examiner for American Board of Psychiatry and Neurology	2014

PUBLICATIONS

Perry MS, Nascimento FA, Pina-Garza JE, Chez MG, Ferreira JA, Rabinowicz AL, Carrazana E. Addressing barriers to transitioning pediatric patients with epilepsy to adult health care in the United States: a narrative review. *Neurology: Clinical Practice*. 2026;16(3):e200616. https://www.neurology.org/doi/10.1212/CPJ.0000000000200616

Arzimanoglou, A., Ferreira, J. A., Satlin, A., Mendes, S., Williams, B., Critchley, D., Schuck, E., Hussein, Z., Kumar, D., Dhadda, S., & Bibbiani, F. (2016). Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox-Gastaut syndrome: An interim analysis from a multicenter, randomized, active-controlled, open-label study. *European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society*, *20*(3), 393–402. https://doi.org/10.1016/j.ejpn.2015.12.015

Benbadis, S. R., Anthony, K., Caines, G., Hess, G., Jackson, C., Tatum IV, W. O., Ferreira, J., Gieron-Korthals, M., Vale, F. L. (2005, August 2). a prolonged and multi-modality technique for inducing pseudoseizures: preliminary results. *Epilepsia*, *40*(S7), 100. https://doi.org/10.1111/j.1528-1157.1999.tb01726.x

Carr, S. B., Bergamo, D. F., Emmanuel, P. J., & Ferreira, J. A. (2014). Murine typhus as a cause of cognitive impairment: case report and a review of the literature. *Pediatric neurology*, *50*(3), 265–268. https://doi.org/10.1016/j.pediatrneurol.2013.09.017

Carrazana, E. J., Wheeler, S. D., Bolanos, A., Tatum IV, W. O., Ferreira, J., Ramirez-Mejia, C. (2005, August 2). gabapentin in the treatment of migraine headaches associated with benign sylvian spikes and benign childhood epilepsy. *Epilepsia*, *40*(S7), 114. https://doi.org/10.1111/j.1528-1157.1999.tb01726.x

Ferreira, J. A., Le Pichon, J. B., Abdelmoity, A. T., Dilley, D., Dedeken, P., Daniels, T., & Byrnes, W. (2019). Safety and tolerability of adjunctive lacosamide in a pediatric population with focal seizures - An open-label trial. *Seizure*, *71*, 166–173. https://doi.org/10.1016/j.seizure.2019.05.016

Ferreira, J., Eviatar, L., Schneider, S., & Grossman, R. (1993). Prenatal diagnosis of intracranial teratoma. Prolonged survival after resection of a malignant teratoma diagnosed prenatally by ultrasound: a case report and literature review. *Pediatric neurosurgery*, *19*(2), 84–88. https://doi.org/10.1159/000120706

Ferreira, J., Lacson, A., Raasch, J., & Pomerance, H. H. (2006). Clinico-pathologic conference: status epilepticus in a 5-year-old girl. *Fetal and pediatric pathology*, *25*(1), 21–34. https://doi.org/10.1080/15227950600701487

Grossman, R., Novak, G., Patel, M., Maytal, J., Ferreira, J., & Eviatar, L. (1993). MRI in neonatal dural sinus thrombosis. *Pediatric neurology*, *9*(3), 235–238. https://doi.org/10.1016/0887-8994(93)90093-r

Jacinto, S. J., Gieron-Korthals, M., & Ferreira, J. A. (2001). Predicting outcome in hypoxic-ischemic brain injury. *Pediatric clinics of North America*, *48*(3), 647–660. https://doi.org/10.1016/s0031-3955(05)70332-1

Ng, Y., Glauser, T., Ferreira, J., Olhaye, O., Williams, B., Perdomo, C., Bibbiani, F. (2016, April 5). Response Durability Analyses from a Rufinamide Pivotal Trial in Lennox-Gastaut Syndrome (LGS). *Neurology Journals*, *86*(16). https://doi.org/10.1212/WNL.86.16_supplement.P2.043

Prust, M., Wang, J., Morizono, H., Messing, A., Brenner, M., Gordon, E., Hartka, T., Sokohl, A., Schiffmann, R., Gordish-Dressman, H., Albin, R., Amartino, H., Brockman, K., Dinopoulos, A., Dotti, M. T., Fain, D., Fernandez, R., Ferreira, J., Fleming, J., Gill, D., … Vanderver, A. (2011). GFAP mutations, age at onset, and clinical subtypes in Alexander disease. *Neurology*, *77*(13), 1287–1294. https://doi.org/10.1212/WNL.0b013e3182309f72

Sperling, M. R., French, J., Jacobson, M. P., Pazdera, L., Gough, M., Cheng, H., Grinnell, T., Blum, D., & Study 045 and 046 Investigators (2016). Conversion to eslicarbazepine acetate monotherapy: A pooled analysis of 2 phase III studies. *Neurology*, *86*(12), 1095–1102. https://doi.org/10.1212/WNL.0000000000002497

Szafranski, P., Von Allmen, G. K., Graham, B. H., Wilfong, A. A., Kang, S. H., Ferreira, J. A., Upton, S. J., Moeschler, J. B., Bi, W., Rosenfeld, J. A., Shaffer, L. G., Wai Cheung, S., Stankiewicz, P., & Lalani, S. R. (2015). 6q22.1 microdeletion and susceptibility to pediatric epilepsy. *European journal of human genetics : EJHG*, *23*(2), 173–179. https://doi.org/10.1038/ejhg.2014.75

Tatum, W. O., 4th, Ferreira, J. A., Benbadis, S. R., Heriaud, L. S., Gieron, M., Rodgers-Neame, N. T., & Vale, F. L. (2004). Vagus nerve stimulation for pharmacoresistant epilepsy: clinical symptoms with end of service. *Epilepsy & behavior : E&B*, *5*(1), 128–132. https://doi.org/10.1016/j.yebeh.2003.10.014

Tatum, W. O., 4th, Moore, D. B., Stecker, M. M., Baltuch, G. H., French, J. A., Ferreira, J. A., Carney, P. M., Labar, D. R., & Vale, F. L. (1999). Ventricular asystole during vagus nerve stimulation for epilepsy in humans. *Neurology*, *52*(6), 1267–1269. https://doi.org/10.1212/wnl.52.6.1267

Tatum, W. O., 4th, Winters, L., Gieron, M., Passaro, E. A., Benbadis, S., Ferreira, J., & Liporace, J. (2001). Outpatient seizure identification: results of 502 patients using computer-assisted ambulatory EEG. *Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society*, *18*(1), 14–19. https://doi.org/10.1097/00004691-200101000-00004

Tatum, W. O., Johnson, K. D., Goff, S., Ferreira, J. A., & Vale, F. L. (2001). Vagus nerve stimulation and drug reduction. *Neurology*, *56*(4), 561–563. https://doi.org/10.1212/wnl.56.4.561

BASIC SCIENCE RESEARCH

Michael Leung, PhD and ***J. A. Ferreira, MD***: Processing and Secretion of Procollagen in chick embryo tendon tissue culture: SUNY, College at Old Westbury, NY 1980-1982. Abstract presented at Minority Biomedical Support Program (MBRS) Symposium; New Mexico 04/82

SPONSOR-INITIATED, MULTICENTER CLINICAL TRIALS

Completed or Currently in Progress

Protocol LP352-303: A Phase 3, Open-Label Study to Investigate the Long-Term Safety and Efficacy of LP352 in the Treatment of Seizures in Children and Adults with Developmental and Epileptic Encephalopathy (Principal Investigator)

Protocol LP352-301: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Efficacy, Safety, and Tolerability of LP352 in the Treatment of Seizures in Children and Adults with Developmental and Epileptic Encephalopathies (Principal Investigator)

Protocol LP352-302: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Efficacy, Safety, and Tolerability of LP352 in the Treatment of Seizures in Children and Adults with Dravet Syndrome (Principal Investigator)

Protocol 20160354: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Chronic Migraine (OASIS Pediatric [CM]) (Role: Principal Investigator)

Protocol 20150125: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Episodic Migraine (OASIS Pediatric [EM]) (Role: Principal Investigator)

Protocol BHV7000-303: A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Refractory Focal Onset Epilepsy (Role: Principal Investigator)

Protocol BHV7000-201: A Phase 2, Global, Multicenter, Long-term Safety Study Designed to Assess the Safety and Tolerability of BHV-7000 in Subjects with Refractory Focal Onset Epilepsy (Role: Principal Investigator)

Protocol EBS-101-TD-301: A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Safety and Maintenance of Efficacy of Ecopipam in Children, Adolescents and Adults with Tourette's Disorder (Role: Principal Investigator)

Protocol EBS-101-TD-391: A Multicenter, Open-Label, Study to Evaluate the Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults with Tourette's Disorder (Role: Principal Investigator)

Protocol YKP509C003: A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Carisbamate (YKP509) as Adjunctive Treatment for Seizures Associated with Lennox-Gastaut Syndrome in Children and Adults, with Optional Open-Label Extension (Role: Principal Investigator)

Protocol ADA4003: Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (RE-DAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR™ in treatment of adult and adolescent patients with ADHD in the United States (Role: Principal Investigator)

Protocol N01269: A Randomized, Dose-Finding and Confirmatory, Double-Blind, Placebo-Controlled, Parallel-Group Multicenter Study with a 2-Stage and Adaptive Design and Randomized Withdrawal to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age with Childhood Absence Epilepsy or Juvenile Absence Epilepsy (Role: Principal Investigator)

Protocol EP0132: A Multicenter, Open-label, Single-arm Study to Evaluate Long-term Safety, Tolerability, and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age with Childhood Absence Epilepsy or Juvenile Absence Epilepsy (Role: Principal Investigator)

Protocol LNN-801: CORE-VNS: Comprehensive **O**utcomes **R**egistry in Subjects with **E**pilepsy Treated with **V**agus **N**erve **S**timulation Therapy® (Role: Principal Investigator)

Protocol E2007-G000-236: An Open-Label Study with Extension Phase to Evaluate the Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Subjects (Age 1 Month to Less Than 18 Years) With Childhood Epilepsy (Role: Principal Investigator)

Protocol SP0967: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects with Epilepsy ≥1 Month to <4 Years of Age with Partial-Onset Seizures (Role: Principal Investigator)

Protocol EP0034: A Multicenter, Open-Label, Long-Term Extension Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Pediatric Subjects with Epilepsy with Partial-Onset Seizures (Role: Principal Investigator)

Protocol INS011-17-103: A Phase 2, Open-Label, Dose-finding Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Patients with Treatment-Resistant Childhood Absence Seizures (Role: Principal Investigator)

Protocol INS011-17-113: A Multicenter, Open-Label, Flexible Dose Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Patients with Treatment-Resistant Childhood Absence Seizures (Role: Principal Investigator)

Protocol TV50717-CNS-30080: A Randomized, Double-Blind, Placebo-Controlled Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents (RECLAIM-DCP) (Role: Principal Investigator)

Protocol TV50717-CNS-30081: An Open-Label, Long-Term Safety, Tolerability, and Efficacy Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents (Open RECLAIM-DCP) (Role: Principal Investigator)

Protocol 331-201-00148: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder (Role: Principal Investigator)

Protocol 331-201-00191: A Phase 3, Multicenter, Open-label Trial to Evaluate the Long-term Safety and Tolerability of Brexpiprazole (OPC-34712) in the Treatment of Children and Adolescents with Irritability Associated with Autism Spectrum Disorder (Role: Principal Investigator)

Protocol IPX229-B16-01: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of Zolmitriptan Nasal Spray for the Treatment of Acute Migraine in Subjects Ages 6 to 11 Years, With an Open-Label Extension (Role: Principal Investigator)

Protocol EBS-101-CL-001: A Multicenter, Placebo-Controlled, Double-Blind, Randomized, Parallel-Group, Phase 2b Study to Evaluate the Efficacy and Safety of Ecopipam Tablets in Children and Adolescent Subjects with Tourette's Syndrome (Role: Principal Investigator)

Protocol EBS-101-OL-001: A Multicenter, Open-Label, Extension Study Intended to Evaluate the Long-term Safety of Ecopipam Tablets in Children and Adolescent Subjects with Tourette's Syndrome (Role: Principal Investigator)

Protocol GWEP18060: An Open-Label **E**x**P**loratory **I**nvestigation of **COG**nitive Outcomes with Cannabidiol Oral Solution (EPIDIOLEX®; GWP42003-P) (EPI-COG) (Role: Principal Investigator)

Protocol A4091065: A Protocol to Monitor From Birth To Age 15 Months The Neurological Development Of Infants With Exposure In-Utero In Tanezumab Clinical Studies At All Investigational Sites (Role: Sub-Investigator)

Protocol SP0982: A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Lacosamide as Adjunctive Therapy for Uncontrolled Primary Generalized Tonic-Clonic Seizures in Subjects with Idiopathic Generalized Epilepsy (Role: Principal Investigator)

Protocol EP0012: An Open-Label, Multicenter Extension Study to Evaluate the Long-Term Safety and Efficacy of Lacosamide as Adjunctive Therapy for Uncontrolled Primary Generalized Tonic-Clonic Seizure sin Subjects with Idiopathic Generalized Epilepsy (Role: Principal Investigator)

Protocol D1220C00001: A Multicenter, Double-blind, Randomized, Placebo-controlled, 4-Armed Parallel Group Study to Evaluate the Efficacy of Zolmitriptan 0.5-, 2.5- and 5-mg Nasal Spray in the Treatment of Acute Migraine Headache in Adolescents (Role: Principal Investigator)

Protocol 31-12-293: A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Fixed-Dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder (Role: Principal Investigator)

Protocol 31-12-294: An Open-Label, Multicenter Study Evaluating the Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents with Tourette's Disorder (Role: Principal Investigator)

Protocol A0081106: A 12-Month Open-Label Study to Evaluate the Safety and Tolerability of Pregabalin as Adjunctive Therapy in Pediatric Subjects 1 Month to 16 Years of Age with Partial Onset Seizures and Pediatric and Adult Subjects 5 to 65 Years of Age with Primary Generalized Tonic-Clonic Seizures (Role: Principal Investigator)

Protocol E2007-G000-232: An Open-label Pilot Study with an Extension Phase to Evaluate the Pharmacokinetics, and to Generate Preliminary Safety, Tolerability, and Efficacy of Perampanel (E2007) Oral Suspension When Given as an Adjunctive Therapy in Pediatric Subjects From 2 to Less Than 12 Years of Age with Epilepsy (Role: Principal Investigator)

Protocol M02-552: A Study of the Safety and Efficacy of Depakote Sprinkle Capsules in the Treatment of Partial Seizures in Children (Role: Principal Investigator)

Protocol M04-714: An Open-Label Multicenter Study of the Long-Term Safety of Depakote® Sprinkle Capsules in the Treatment of Partial Seizures in Children (Role: Principal Investigator)

Protocol N01103: A 19-week, Randomized, Double-blind, Multicenter, Placebo controlled Safety study to Evaluate the Cognitive and Neuropsychological Effects of Levetiracetam 20-60 mg/kg/d, Divided in Twice Daily Dosing, as Adjunctive Treatment in Children 4-16 Years Old, Inclusive, with Partial Onset Seizures (Role: Principal Investigator)

Protocol N01009: A Double-Blind, Randomized, Multicenter, Placebo-Controlled, In-Patient, Maximum 34 Day Study of Levetiracetam Oral Solution (20-50 mg/kg/day) as Adjunctive Treatment of Refractory Partial Onset Seizures in Pediatric Epileptic Subjects Ranging in Age from 1 Month to Less Than 4 years of Age (Role: Principal Investigator)

Protocol N01148: A Multi-Center, Open-Label, Long-Term, Follow-Up Study Of the Safety And Efficacy Of Levetiracetam In Children With Partial Onset Seizures (Role: Principal Investigator)

Protocol CAPSS-368: A Long-Term, Open-Label Safety Study of Oral Almotriptan Malate 12.5 mg in the Treatment of Migraine in Adolescents (Role: Principal Investigator)

Protocol TOPMAT-PEP-3001: A Randomized, Double-Blind, Placebo-Controlled, Fixed Dose-Ranging Study to Assess the Safety, Tolerability, and Efficacy of Topiramate Oral Liquid and Sprinkle Formulations as an Adjunct to Concurrent Anticonvulsant Therapy for Infants (1-23 Months of Age, Inclusive) With Refractory Partial-Onset Seizures, with Open-Label Extension (Role: Principal Investigator)

Protocol TOPMAT-PEP-1002: A Randomized, Open-Label, Multicenter Study with Open-Label Extension of the Pharmacokinetics and Safety of Topiramate Administered as the Oral Liquid and Sprinkle Formulations as an Adjunct to Concurrent Anticonvulsant Therapy for Infants (1-24 Months of Age) With Refractory Partial-Onset Seizures (Role: Principal Investigator)

Protocol OV-1012: A Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam in Patients With Lennox-Gastaut Syndrome (Role: Principal Investigator)

Protocol OV-1004: Safety and Effectiveness of Open-Label Clobazam in Subjects with Lennox-Gastaut Syndrome (Role: Principal Investigator)

Protocol OV-1002: Safety and Efficacy of Clobazam in Subjects With Lennox-Gastaut Syndrome (Role: Principal Investigator)

Protocol A0081074: A Placebo-Controlled, Escalating Dose, Multiple Dose Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Pregabalin In Pediatric Patients With Partial Onset Seizures (Role: Principal Investigator)

Protocol A0081075: A 12-Month, Open-Label Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Pregabalin In Pediatric Patients With Partial Onset Seizures (Role: Principal Investigator)

Protocol A0081041: A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 4 – 16 Years Of Age With Partial Onset Seizures (Role: Principal Investigator)

Protocol A0081042: A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 1 Month Through < 4 Years Of Age With Partial Onset Seizures (Role: Principal Investigator)

Protocol E2007-G000-304: A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures (Role: Principal Investigator)

Protocol E2007-G000-307: An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Studies to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory partial Seizures (Role: Principal Investigator)

Protocol E2007-G000-235: An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group studies to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures (Role: Principal Investigator)

Protocol E2007-G000-401: An Extended Access Program for Perampanel

Protocol 093-045: Double-Blind, Randomized, Historical Control Study of the Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects Sith Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs (Role: Principal Investigator)

Protocol 093-050: Long-Term Eslicarbazepine Acetate Extension Study (Role: Principal Investigator)

Protocol BIA-2093-304: Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures in a Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Trial (Role: Principal Investigator)

Protocol CARISEPY3007: A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Evaluate the Retention Rate, Efficacy, Safety and Tolerability of Carisbamate, Topiramate and Levetiracetam as Adjunctive Therapy in Subjects With Partial Onset Seizures (Role: Principal Investigator)

Protocol 804P107: A Multicenter, Open-Label, Multiple Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of OXC XR as Adjunctive Therapy in Pediatric Subjects with Refractory Partial Epilepsy (Role: Principal Investigator)

Protocol 804P303: A Multicenter, 12-Month, Open-Label Extension Study to 804P107 (Role: Principal Investigator)

Protocol SP847: A Multicenter, Open-Label Study To Determine Safety, Tolerability and Pharmacokinetics of Lacosamide (LCM) Oral Solution (Syrup) as Adjunctive Therapy In Children with Partial-Onset Seizures (Role: Principal Investigator)

Protocol SP848: An Open-Label Study to Determine Safety, Tolerability, and Efficacy of Long-Term Oral Lacosamide (LCM) as Adjunctive Therapy in Children With Epilepsy (Role: Principal Investigator)

Protocol SP0969: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects With Epilepsy ≥4 Years to < 17 Years of Age With Partial-Onset Seizures (Role: Principal Investigator)

Protocol SP902: A Historical-Controlled, Multicenter, Double-Blind, Randomized Trial to Assess the Efficacy and Safety of Conversion to Lacosamide 400mg/Day Monotherapy in Subjects With Partial-Onset Seizures (Role: Principal Investigator)

Protocol SP904: A Multicenter, Open-Label Extension Trial to Assess the Long-Term Use of Lacosamide Monotherapy and Safety of Lacosamide Monotherapy and Adjunctive Therapy in Subjects With Partial-Onset Seizures (Role: Principal Investigator)

Protocol P261-401: A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Intranasal Midazolam (USL261) in the Outpatient Treatment of Subjects With Seizure Clusters. ARTEMIS-1: Acute Rescue Therapy in Epilepsy With Midazolam Intranasal Spray-1 (Role: Principal Investigator)

Protocol P261-402: An Open-Label Safety Study of USL261 in the Outpatient Treatment of Subjects With Seizure Clusters

Protocol E2080-G000-303: A Multicenter, Randomized, Controlled, Open-label Study to Evaluate the Cognitive Development Effects and Safety, and Pharmacokinetics of Adjunctive Rufinamide Treatment in Pediatric Subjects 1 to Less Than 4 Years of Age with Inadequately Controlled Lennox-Gastaut Syndrome (Role: Principal Investigator)

Protocol RTG113284: Open-label, Multiple Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Ezogabine/Retigabine as Adjunctive Treatment in Subjects Aged From 12 Years to Less Than 18 Years With Partial Onset Seizures or Lennox-Gastaut Syndrome (Role: Principal Investigator)

Protocol K826-05-3001 / B45-11-001: A Phase 3, Randomized, Double-Blind, Parallel, Placebo-controlled, Multicenter Study, With Optional Open-label Continuation, Of The Efficacy And Safety Of Vanquix™ Auto-injector (Diazepam Injection) For The Management Of Selected, Refractory, Patients With Epilepsy Who Require Intermittent Medical Intervention To Control Episodes Of Acute Repetitive Seizures (Role: Principal Investigator)

Protocol M03-648: An Open-Label, Long-Term Safety Study of Divalproex Sodium Extended-Release Tablets for Migraine Prophylaxis in Adolescents (Role: Principal Investigator)

Protocol 333369-EPY-3002/333369-EPY-3004: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of RWJ 333369 as Adjunctive Therapy in Subjects With Partial Onset Seizures Followed by an Open-Label Extension Study: Open-Label Extension Period (Role: Principal Investigator)

Protocol 190-246: A Randomized, Placebo-Controlled, Double Blind, Fixed Dose Study of the Efficacy and Safety of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) with Attention Deficit/Hyperactivity Disorder Associated Insomnia (Role: Principal Investigator)

Protocol 190-247: A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia (Role: Principal Investigator)

Protocol LAM100118: An Open-Label Evaluation of Lamictal (Lamotrigine) Monotherapy for the Treatment of Newly Diagnosed Typical Absence Seizures in Children and Adolescents (Role: Principal Investigator)

Protocol LAM20006: A Double-Blind, Placebo-Controlled, Add-On Clinical Trial of the Safety, Pharmacokinetics and Efficacy of Lamictal in Pediatric Age Subjects (1-24 months) (Role: Principal Investigator)

Protocol LAM20007: An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of Lamictal in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and in Lamictal-naïve Subjects (1-24 Months of Age) (Role: Principal Investigator)

Protocol 1042-0500: A Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Antiepileptic Activity of Ganaxolone in Treatment of Patients With Infantile Spasms (Role: Principal Investigator)

Protocol 1042-0501: An Open-label Clinical Study to Evaluate the Safety and Antiepileptic Activity of Ganaxolone in Treatment of Patients Diagnosed With Infantile Spasms (Role: Principal Investigator)

Protocol CAPSS-311: A Multicenter, Outpatient, Open Label Study to Evaluate the Dosing, Effectiveness and Safety of Topamax as Monotherapy in the Treatment of Epilepsy in Clinical Practice TIME (Topamax Initiated as Monotherapy in Epilepsy) (Role: Principal Investigator)

****A Pilot Study**: A study of Tiagabine in Infantile Spasms (Role: Principal Investigator)

**A multi-center, double-blind, randomized, placebo-controlled, parallel-group evaluation of Lamotrigine adjunctive therapy in subjects with primary generalized tonic-clonic seizures (Role: Principal Investigator)

**An open label, randomized, parallel-group, multi-center trial to compare a stratified care treatment regimen based on migraine disability (MIDAS grade) versus standard therapy for the acute treatment of migraine headache (Role: Principal Investigator)

**A multi-center, randomized, double-blind, placebo-controlled, parallel trial comparing the safety and efficacy of Rufinamide as adjunctive therapy relative to placebo in patients with inadequately controlled Lennox-Gastaut Syndrome (Role: Principal Investigator)

**An open-label, multi-center study to assess tolerability, effectiveness and quality of life associated with the use of SLI 381 (Adderall XR) in children with attention deficit hyperactivity disorder (ADHD) in a community practice setting (A Phase IIIB Study) (Role: Principal Investigator)

**An open-label, long-term safety study of Zonisamide (Zonegran) administered to children with epilepsy (Role: Principal Investigator)

Protocol N159: Evaluation of the Efficacy and Tolerability of Levetiracetam Add-On Treatment in Refractory Pediatric Patients With Partial Onset Seizures: A 28-Week Double-Blind, Placebo-Controlled Multi-center Trial (Role: Principal Investigator)

Protocol UCB L059: A Multi-center, Open-Label, Long-Term Follow-Up Study of the Safety and Efficacy of Levetiracetam in Children with Epilepsy (Role: Principal Investigator)

**Pharmacokinetic study of Phosphenytoin IV in infants and children (Role: Principal Investigator)

**A multi-center, double-blind, placebo-controlled trial of Tiagabine HCL in pediatric patients with partial seizures (Role: Co-Principal Investigator)

Protocol N91-604: Open-label extension study of Tiagabine HCL in the treatment of patients with partial seizures (Role: Sub-Investigator / Principal Investigator: R.E. Ramsay, MD)

****Protocol YP**: Topiramate clinical trial in children with partial onset seizures (Role: Principal Investigator)

****Protocol YTC**: Topiramate clinical trial of primary generalized seizures (Role: Principal Investigator)

Protocol 810-921: Long-term, safety and efficacy evaluation of Zonisamide in the treatment of seizures of medically refractory patients, and efficacy evaluation of Zonisamide monotherapy (Role: Sub-Investigator / Principal Investigator: R. E. Ramsay, MD)

Protocol M92-813: An open-label study of the safety of long-term Tiagabine-HCL administration in patients with epilepsy (Role: Sub-Investigator / Principal Investigator: R. E. Ramsay, MD)

Protocol 810-920: Base-line control, safety and efficacy evaluation of Zonisamide in the treatment of seizures in medically refractory patients (Role: Sub-Investigator / Principal Investigator: R. E. Ramsay, MD)

**An open-label, long-term safety study of Vigabatrin administered concomitantly with antiepileptic drugs or as monotherapy (Role: Sub-Investigator / Principal Investigator: R. E. Ramsay, MD)

****Protocol 26**: A protocol to provide Lamictal for the therapy of serious or life-threatening seizures (Role: Sub-Investigator / Principal Investigator: R. E. Ramsay, MD)

Protocol 945-82: A double-blind, dose-controlled, multi-center study of the conversion from marketed antiepileptic drug therapy to Gabapentin monotherapy in patients with complex partial or secondary generalized seizures (Role: Sub-Investigator / Principal Investigator: R. E. Ramsay, MD)

Protocol 265: VA cooperative study of the treatment of generalized convulsive status epilepticus (Role: Sub-Investigator / Director: David Trieman, MD / Principal Investigator: R. E. Ramsay, MD)

**A double-blind trial of Topiramate in patients with Lennox-Gastaut Syndrome (Role: Principal Investigator)

**A multi-center, double-blind, placebo-controlled, parallel design evaluation of Lamictal for add on treatment of partial seizures in pediatric patients (Role: Principal Investigator)

****Protocol BECTS**: A multi-center, double-blind, placebo-controlled, parallel-group study of Gabapentin monotherapy in pediatric patients with benign childhood epilepsy with central temporal spikes (BECTS) (Role: Principal Investigator)

**An extended, open-label, Gabapentin pediatric monotherapy trial following a double-blind study in pediatric patients with BECTS (Role: Principal Investigator)

Thesis for MD Degree: Comparative study of the incidence of drug addiction and other common psychiatric disorders, UCE Medical Center, 1985 (Authors: J.A. Ferreira; J. Luna; J. Garcia)

CONFERENCES / PRESENTATIONS (ACTIVITY BETWEEN 1995-2004 ONLY subsequent activity not recorded)

"What Epilepsy is All About" Parent and family training seminar at All Children's Hospital – May 13, 1995

"Mastering Epilepsy" A regional consultants meeting, Newport Beach, CA Special patients' population, pediatric cases – July 30, 1995

"Nonketotic Hyperglycinemia" at All Children's Hospital, case conference – October 11, 1995

"Update on Childhood Epilepsy" at Manatee Memorial Hospital, Pediatrics Department – January 20, 1995

"Neonatal Seizures" at Morton Plant, Florida Society of Electrodiagnostic Technologists – January 20, 1996

"Carnitine Deficiency" at All Children's Hospital, case conference – February 14, 1996

"Paroxysmal Events in Children" at All Children's Hospital, case conference – June 19, 1996

"Headaches in Pediatrics" Suncoast Pediatric Conference, at Don Cesar Hotel, St Petersburg, FL – June 24, 1996
"Pediatric Neurology: Focus on Epilepsy" at Marco Island Hilton, FL – October 6, 1996

"EPICON Children with Epilepsy" at Sarasota Memorial Hospital, Sarasota, FL – October 6, 1996

"Drug Effects on the Electroencephalogram", Florida Society of Electrodiagnostic Technologists in Daytona Beach, FL – January 20, 1997

"Infantile Spasms" Consensus conference in the management of epilepsy in children at Mission Inn, Howey-in-the-Hills, FL – May 9, 1997

"Update on Pediatric Epilepsy" Health South Rehabilitation Symposium – July 25, 1997

"Practical Issues in Epilepsy Management" Pediatric Epilepsy Syndromes at Busch Gardens, Tampa, FL (USF School of Medicine, CME Program) – October 8, 1997

"Febrile Seizures" Case presentation at All Children's Hospital – December 10, 1997

"Tuberculosis Meningitis" Case presentation at All Children's Hospital – April 8, 1998

"The Anatomy of the Spinal Cord" during "Inside the O.R." conference on intra-operative monitoring American Society of Electrodiagnostic Technologists, Clearwater, FL – April 24, 1998

"Intra-operative Motor Evoked Potential Monitoring" during "Inside the O.R." conference on intra-operative monitoring American Society of Electrodiagnostic Technologists, Clearwater, FL – April 25, 1998

"The New Anti-Convulsant" Presented to general neurologist and child neurologists at the Hyatt Regency Hotel, Tampa, FL – May 7, 1998

"The New Anti-Epileptic Drugs" during "Fishing for Action" presented to neurology consultants in Pensacola, FL – May 30, 1998

"Childhood Epilepsy Syndromes: New Treatments" presented to adult and child neurologists by the University of Miami, School of Medicine (CME) at The Innisbrook, Tarpon Springs, FL – June 27, 1998

"Review of Pediatric Epilepsy and Epilepsy Syndromes" presented to the Hillsborough Epilepsy Association, Tampa, FL – July 24, 1998